論文

査読有り 最終著者 国際誌
2021年8月1日

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.

Japanese journal of clinical oncology
  • Takashi Ninomiya
  • Naoyuki Nogami
  • Toshiyuki Kozuki
  • Daijiro Harada
  • Toshio Kubo
  • Kadoaki Ohashi
  • Eiki Ichihara
  • Shoichi Kuyama
  • Kenichiro Kudo
  • Akihiro Bessho
  • Makoto Sakugawa
  • Nobukazu Fujimoto
  • Keisuke Aoe
  • Daisuke Minami
  • Keisuke Sugimoto
  • Nobuaki Ochi
  • Nagio Takigawa
  • Katsuyuki Hotta
  • Yoshinobu Maeda
  • Katsuyuki Kiura
  • 全て表示

51
8
開始ページ
1269
終了ページ
1276
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/jjco/hyab084

BACKGROUND: In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients. METHODS: Chemo-naïve patients with EGFR-mutant advanced non-small-cell lung cancer were enrolled. One group of patients received 40 mg afatinib daily and 15 mg/kg bevacizumab every 3 weeks (level 0) until disease progression or severe toxicity. Another group of patients received 30 mg afatinib daily and the same dose of bevacizumab (level 1). Dose-limiting toxicity was the primary endpoint, whereas long-term progression-free survival, overall survival and tolerability were secondary endpoints. Survival rates were estimated using the Kaplan-Meier method. RESULTS: The study included 19 patients (level 0: 5; level - 1: 14). Until the data cut-off date, seven patients continued the treatment, whereas 12 discontinued due to disease progression (n = 5) or toxicity (n = 7). The median PFS was 24.2 months, while the median overall survival was not reached. All patients developed adverse effects. Diarrhoea and skin rash were frequently observed as severe adverse events (grade 3). A secondary EGFR mutation (T790M) was detected in two patients after progression. CONCLUSIONS: Prolonged follow-up revealed that combination therapy with afatinib and bevacizumab might improve survival outcomes in EGFR-mutant advanced non-small-cell lung cancer patients and seems to be promising. TRIAL REGISTRATION: UMIN000015944.

リンク情報
DOI
https://doi.org/10.1093/jjco/hyab084
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34115855
ID情報
  • DOI : 10.1093/jjco/hyab084
  • PubMed ID : 34115855

エクスポート
BibTeX RIS